Skip to main content

Management of Chronic Lymphocytic Leukemia - Use of Novel Therapies in Treatment while Remediating Adverse Events

2 of 20 Sessions Available

  • JUN
    10
    June 10, 2020
    Wed 4:00 PM EDT 1H
    Closed
    • The avatar for the contributor named PAUL M. BARR, MD. PAUL M. BARR, MD
    • The avatar for the contributor named RYAN W. JACOBS, MD. RYAN W. JACOBS, MD
  • SEP
    01
    September 01, 2020
    Tue 4:00 PM EDT 1H
    Closed
    • The avatar for the contributor named RYAN W. JACOBS, MD. RYAN W. JACOBS, MD
  • SEP
    03
    September 03, 2020
    Thu 4:00 PM EDT 1H
    Closed
  • SEP
    08
    September 08, 2020
    Tue 2:00 PM EDT 1H
    Closed
  • OCT
    08
    October 08, 2020
    Thu 12:30 PM EDT 1H
    Closed
  • OCT
    15
    October 15, 2020
    Thu 12:00 PM EDT 1H
    Closed
  • NOV
    18
    November 18, 2020
    Wed 12:00 PM EST 1H
    Closed
  • NOV
    19
    November 19, 2020
    Thu 12:00 PM CST 1H
    Closed
  • NOV
    25
    November 25, 2020
    Wed 7:00 AM EST 1H
    Closed
  • DEC
    02
    December 02, 2020
    Wed 11:30 AM EST 1H
    Closed
  • DEC
    11
    December 11, 2020
    Fri 8:00 AM EST 1H
    Closed
  • JAN
    12
    January 12, 2021
    Tue 7:00 AM CST 1H
    Closed
  • JAN
    13
    January 13, 2021
    Wed 12:00 PM EST 1H
    Closed
  • JAN
    15
    January 15, 2021
    Fri 8:00 AM EST 1H
    Closed
  • JAN
    22
    January 22, 2021
    Fri 12:00 PM EST 1H
    Closed
  • FEB
    09
    February 09, 2021
    Tue 12:00 PM EST 1H
    Closed
  • FEB
    10
    February 10, 2021
    Wed 8:00 AM EST 1H
    Closed
  • FEB
    12
    February 12, 2021
    Fri 12:00 PM EST 1H
    Closed
  • MAR
    10
    March 10, 2021
    Wed 12:30 PM EST 1H
    Seats Available
    • The avatar for the contributor named RYAN W. JACOBS, MD. RYAN W. JACOBS, MD
  • MAR
    11
    March 11, 2021
    Thu 8:00 AM EST 1H
    Seats Available

Contributors

  • PAUL M. BARR, MD

    Medical Director, Clinical Trial Office
    Associate Professor of Medicine
    James P. Wilmot Cancer Institute
    University of Rochester Medical Center
    Rochester, NY

    Paul M. Barr, MD is an Associate Professor of Medicine and the Medical Director of the Clinical Trials Office (CTO) at the James P. Wilmot Cancer Institute at the University of Rochester Medical Center. His internal medicine and hematology oncology training were completed at Case Western Reserve University; the latter supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) K12 award. Additional clinical research training was achieved through the American Society of Hematology Clinical Research Training Institute.

    Dr. Barr’s research is focused on the development of novel treatment combinations for lymphoma and chronic lymphocytic leukemia. He has led several single institution, multi-center and cooperative group studies. His early research was supported by pilot grants from the Wilmot Fellowship and the Rochester NIH Specialized Program of Research Excellence Award in Lymphoma, as well as a career development grant awarded by the Lymphoma Research Foundation. Ongoing research includes: 1) defining treatment for early progressing follicular lymphoma through the National Clinical Trials Network supported SWOG 1608 trial; 2) incorporating PI3K inhibition into the treatment armamentarium through an investigator-initiated multicenter study of umbralisib, ublituximab, and venetoclax; and 3) further defining the role of first-line BTK inhibition in CLL through a single-center investigator-initiated study of an acalabrutinib-based combination.

    Dr. Barr’s focus on clinical-trial design and an administrative position as the CTO Director is supported by an NCI National Clinical Trials Network Lead Academic Participating Site Award, for which he serves as Principal Investigator (PI). He also serves as University of Rochester PI for the SWOG oncology cooperative group and sits on the SWOG Board of Governors. He remains active in the Association of American Cancer Institutes, Clinical Research Initiative, having previously served on the group’s steering committee.

  • RYAN W. JACOBS, MD

    Principal Investigator, Lymphoma Section
    Levine Cancer Institute
    Atrium Health
    Charlotte, NC

    Ryan W. Jacobs, MD joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015 and has served as a clinician and Principal Investigator in the Lymphoma Section since that time. His clinical practice is comprised of patients with diagnoses of Hodgkin’s and non-Hodgkin’s lymphoma. Dr. Jacobs has both a clinical and research focus on patients with chronic lymphocytic leukemia (CLL). In his role as a Principal Investigator, he oversees the clinical trials conducted at LCI that involve the treatment of patients with CLL. As the CLL expert for the LCI/Atrium Health system, he is responsible for creating and overseeing the patient care pathways involving the treatment of CLL patients in a network that spans North and South Carolina.

    In addition to clinical trials, Dr. Jacobs has a research interest in real-world outcomes of patients with CLL on novel therapies and has contributed to this field of research by evaluating patients across North and South Carolina treated in a variety of clinical settings. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015. Dr. Jacobs is board-certified in hematology, medical oncology, and internal medicine. Through LCI’s adjunct affiliation, Dr. Jacobs is an Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

2 of 20 Sessions Available